Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
101-PGC-005 + standard of care
- Development stage
- Unknown
- Lead developer
- PIF Partners
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
101-PGC-005 is a Type IA prodrug of dexamethasone designed to selectively target CD206+ (mannose receptor-positive) activated macrophages. This targeted delivery aims to enhance the anti-inflammatory efficacy of dexamethasone while minimizing systemic side effects, particularly suppression of the hypothalamic-pituitary-adrenal (HPA) axis. The drug is being developed for use in combination with standard of care therapies for hospitalized patients with moderate COVID-19 and has also received FDA Rare Pediatric Disease Designation for systemic juvenile idiopathic arthritis (sJIA) flares. In clinical trials, 101-PGC-005 is administered as a bolus injection and compared against conventional dexamethasone therapy, with all patients receiving additional standard treatments as appropriate[1][2][3][4][5].
- Other names
- 005 + standard of care
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on 101-PGC-005 + standard of care.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 101-PGC-005 + standard of care.